Consolidation therapy impact on survival outcomes in young patients with intracranial primary diffuse large B-cell lymphoma achieving complete remission: a propensity score matching analysis
Consolidation therapy improved DFS in young intracranial primary DLBCL patients achieving CR after HD-MTX-based chemotherapy. Autologous stem cell transplantation and radiotherapy showed comparable consolidation benefits. Good performance status correlated with favorable outcomes. Adding rituximab to induction chemotherapy may improve OS in patients without consolidation therapy, but it might be unnecessary for those eligible for consolidation. Further research involving a larger patient cohort is warranted to ascertain rituximab's efficacy.
Authors
- Jijin Wang
- Hanyu Wang (ORCID: https://orcid.org/0000-0001-7933-0667)
- S. Han (ORCID: https://orcid.org/0000-0001-9479-5374)
- Yujing Zhang (ORCID: https://orcid.org/0000-0001-8451-2035)
- Jinshan Zhang (ORCID: https://orcid.org/0000-0001-7360-6837)
- Miao Xiang (ORCID: https://orcid.org/0000-0002-9299-8415)
- Ge Wen
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Guangzhou Medical University (CN)
- Mianyang Central Hospital (CN)
- Key Laboratory of Guangdong Province (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fonc.2025.1493542
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00